The Impact of Immune-checkpoint Inhibition on the Gastrointestinal Tract in Non-small Cell Lung Cancer - PubMed
4 hours ago
- #Immune-checkpoint inhibitors
- #Non-small cell lung cancer
- #Gastrointestinal toxicity
- Immune-checkpoint inhibitor (ICI)-based immunotherapy is a key treatment in onco-hematology, especially for lung cancer.
- Gastrointestinal (GI) toxicity is a common immune-related adverse event (irAE) associated with ICIs.
- Early detection and management of GI irAEs are crucial to prevent severe complications.
- Corticosteroids are the primary treatment for irAEs, but new therapies are emerging to improve outcomes.
- This review focuses on GI toxicities linked to ICIs, their management, and their impact on NSCLC patients.